title: American Society of Clinical Oncology Annual Meeting 2013.
authors.forename: Farhat
authors.initials: F
authors.lastname: Yaqub
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008495:Medical Oncology / Q000379:methods*; D015337:Multicenter Studies as Topic; D010091:Oximes / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*; D012955:Societies, Medical; D013450:Sulfones / Q000627:therapeutic use; D000077210:Sunitinib; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D011799:Quinazolines; C533237:STA 9090; D013450:Sulfones; D043823:Taxoids; D014230:Triazoles; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; C530716:nintedanib; C586847:ceritinib; C561627:dabrafenib; D000077210:Sunitinib